RATIONALE: In aging HIV-infected populations comorbid diseases are important determinants of morbidity and mortality. Pulmonary diseases have not been systematically assessed in the combination antiretroviral therapy (ART) era. OBJECTIVES: To determine the incidence of pulmonary diseases in HIV-infected persons compared with HIV-uninfected persons. METHODS: We analyzed data from the Veterans Aging Cohort Study Virtual Cohort, consisting of 33,420 HIV-infected veterans and 66,840 age, sex, race and ethnicity, and site-matched HIV-uninfected veterans. Using Poisson regression, incidence rates and adjusted incidence rate ratios were calculated to determine the association of HIV with pulmonary disease. The Virtual Cohort was merged with the 1999 Veterans Large Health Survey to adjust for self-reported smoking in a nested sample (14%). MEASUREMENTS AND MAIN RESULTS: Incident chronic obstructive pulmonary disease, lung cancer, pulmonary hypertension, and pulmonary fibrosis, as well as pulmonary infections, were significantly more likely among HIV-infected patients compared with uninfected patients in adjusted analyses, although rates of asthma did not differ by HIV status. Bacterial pneumonia and chronic obstructive pulmonary disease were the two most common incident pulmonary diseases, whereas opportunistic pneumonias were less common. Absolute rates of most pulmonary diseases increased with age, although the relative differences between those with and without HIV infection were greatest in younger persons. Chronic obstructive pulmonary disease and asthma, as well as pulmonary infections, were less likely in those with lower HIV RNA levels and use of ART at baseline. CONCLUSIONS: Pulmonary diseases among HIV-infected patients receiving care within the Veterans Affairs Healthcare System in the combination ART era reflect a substantial burden of non-AIDS-defining and chronic conditions, many of which are associated with aging.
RATIONALE: In aging HIV-infected populations comorbid diseases are important determinants of morbidity and mortality. Pulmonary diseases have not been systematically assessed in the combination antiretroviral therapy (ART) era. OBJECTIVES: To determine the incidence of pulmonary diseases in HIV-infectedpersons compared with HIV-uninfectedpersons. METHODS: We analyzed data from the Veterans Aging Cohort Study Virtual Cohort, consisting of 33,420 HIV-infected veterans and 66,840 age, sex, race and ethnicity, and site-matched HIV-uninfected veterans. Using Poisson regression, incidence rates and adjusted incidence rate ratios were calculated to determine the association of HIV with pulmonary disease. The Virtual Cohort was merged with the 1999 Veterans Large Health Survey to adjust for self-reported smoking in a nested sample (14%). MEASUREMENTS AND MAIN RESULTS: Incident chronic obstructive pulmonary disease, lung cancer, pulmonary hypertension, and pulmonary fibrosis, as well as pulmonary infections, were significantly more likely among HIV-infectedpatients compared with uninfected patients in adjusted analyses, although rates of asthma did not differ by HIV status. Bacterial pneumonia and chronic obstructive pulmonary disease were the two most common incident pulmonary diseases, whereas opportunistic pneumonias were less common. Absolute rates of most pulmonary diseases increased with age, although the relative differences between those with and without HIV infection were greatest in younger persons. Chronic obstructive pulmonary disease and asthma, as well as pulmonary infections, were less likely in those with lower HIV RNA levels and use of ART at baseline. CONCLUSIONS:Pulmonary diseases among HIV-infectedpatients receiving care within the Veterans Affairs Healthcare System in the combination ART era reflect a substantial burden of non-AIDS-defining and chronic conditions, many of which are associated with aging.
Authors: M J Rosen; K Clayton; R F Schneider; W Fulkerson; A V Rao; J Stansell; P A Kvale; J Glassroth; L B Reichman; J M Wallace; P C Hopewell Journal: Am J Respir Crit Care Med Date: 1997-01 Impact factor: 21.405
Authors: Amy C Justice; Elizabeth Dombrowski; Joseph Conigliaro; Shawn L Fultz; Deborah Gibson; Tamra Madenwald; Joseph Goulet; Michael Simberkoff; Adeel A Butt; David Rimland; Maria C Rodriguez-Barradas; Cynthia L Gibert; Kris Ann K Oursler; Sheldon Brown; David A Leaf; Matthew B Goetz; Kendall Bryant Journal: Med Care Date: 2006-08 Impact factor: 2.983
Authors: Kristina Crothers; Joseph L Goulet; Maria C Rodriguez-Barradas; Cynthia L Gibert; Kris Ann K Oursler; Matthew Bidwell Goetz; Stephen Crystal; David A Leaf; Adeel A Butt; R Scott Braithwaite; Robin Peck; Amy C Justice Journal: AIDS Educ Prev Date: 2009-06
Authors: Jessica A Kynyk; Jonathan P Parsons; Michael F Para; Susan L Koletar; Philip T Diaz; John G Mastronarde Journal: Respir Med Date: 2012-01-27 Impact factor: 3.415
Authors: Matthew R Gingo; Mehdi Nouraie; Cathy J Kessinger; Ruth M Greenblatt; Laurence Huang; Eric C Kleerup; Lawrence Kingsley; Deborah K McMahon; Alison Morris Journal: Ann Am Thorac Soc Date: 2018-02
Authors: Alex Kayongo; Adaeze C Wosu; Tasmia Naz; Faith Nassali; Robert Kalyesubula; Bruce Kirenga; Robert A Wise; Trishul Siddharthan; William Checkley Journal: COPD Date: 2020-05-28 Impact factor: 2.409
Authors: Elizabeth V Nguyen; Sina A Gharib; Kristina Crothers; Yu-Hua Chow; David R Park; David R Goodlett; Lynn M Schnapp Journal: Am J Physiol Lung Cell Mol Physiol Date: 2013-11-08 Impact factor: 5.464